---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-043232"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-06-15T20:35:19+00:00"
generated_at: "2026-06-15T20:36:17.472438+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen FY2026 net loss $69.7M; PALISADE-4 topline results expected June 2026

## Summary
- Net loss of $69.7M for FY ended March 31, 2026, vs $51.4M prior year; R&D expense $55.0M.
- Cash and marketable securities $45.4M; management expects runway into 2027.
- Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder; topline results expected in June 2026.
- Received FDA 'Study May Proceed' letter for refisolone IND for menopausal hot flashes.
- Appointed new CMO (Dr. Angel Angelov), CFO (Nick Tressler), and Chief Corporate Development Officer (Elissa Cote).

## SEC filing metadata
- accession: 0001628280-26-043232
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-06-15T20:35:19+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/0001628280-26-043232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/vtgn-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-043232
- JSON: https://secwatch.observer/filing/0001628280-26-043232.json
- Plain text: https://secwatch.observer/filing/0001628280-26-043232.txt

## Key facts
- Earnings Releases
  Vistagen Therapeutics, Inc. reported fiscal year ended March 31, 2026 results: net income $69.7 million.
  - Period: fiscal year ended March 31, 2026
  - Net income: $69.7 million
  - Result: reported results
  source text: Net loss was $69.7 million for the fiscal year ended March 31, 2026, compared with $51.4 million for the fiscal year ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/0001628280-26-043232-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.